Pro 2014-003 (Announcement of Jianfeng Group's Guarantee to Holding Subsidiary)
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Lin 2014-003
Announcement of Zhejiang Jianfeng Group Co., Ltd.
Providing Guarantee to Holding Subsidiaries
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Important Content Tips
● Names of Guarantees: Daye Jianfeng Cement Co., Ltd., Zhejiang Jianfeng Pharmaceutical Co., Ltd., Jinhua Pharmaceutical Co., Ltd., Zhejiang Jianfeng International Trading Co., Ltd., Yunnan Jianfeng Cement Co., Ltd.
● Proposed guarantee amount: set guarantee amount of 0.5 billion yuan.
● Is there any counter-guarantee for this guarantee: No
● Cumulative number of overdue external guarantees: No
Overview of 1. guarantees
On April 11, 2014, Zhejiang Jianfeng Group Co., Ltd. held the 14th meeting of the 8th Board of Directors. Nine directors should be present at the meeting. Independent director Deng Mingran entrusted independent director Liu Jiajian to attend the meeting due to a business trip, and the remaining eight directors attended the meeting in person; they complied with the relevant provisions of the "Company Law" and the "Articles of Association", and the resolutions made were legal and valid. The meeting was presided over by Chairman Jiang Xiaomeng. After deliberation and voting, the "Proposal on Providing Guarantees for Holding Subsidiaries" was reviewed and passed with 9 votes in favor, 0 votes against, and 0 abstentions. Basic information of
2. guarantor
, Zhejiang Jianfeng Pharmaceutical Co., Ltd., with a registered capital of 149.07 million yuan, of which: the company accounts for 99.16, and its registered address is in Jinhua Industrial Park, Zhejiang Province. Its main business is the manufacture, sale and export of eye drops, ear drops, large volume injection, small volume injection and bulk drugs (azithromycin sulfate, L-aspartate amlodipine, paroxidine hydrochloride), freeze-dried powder injection, powder injection (cephalosporins), tablet, hard capsule, granule, ointment, dropping pill, bulk drug , etc. .
2. daye peak cement co., ltd. has a registered capital of 0.25 billion yuan, of which the company accounts for 6% and the company's holding subsidiary Zhejiang peak cement co., ltd. (the company holds 95.25) accounts for 70%. registered address: daye city hubei province security town; main business: cement, cement clinker, cement mechanical and electrical equipment manufacturing and sales; building materials products such as sales.
. Yunnan Jianfeng Cement Co., Ltd. has a registered capital of 0.15 billion yuan, of which: the company accounts for 75%, the holding subsidiary Jianfeng Cement (the company holds 95.25) accounts for 25%, and its registered address is 43 kilometers from Silan Highway, Liushun Township, Simao District, Pu 'er City, Yunnan Province. Its main business is cement production; sales of cement and cement products, building materials, gravel, woven bags, cement grinding; cement export trade.
. Jinhua pharmaceutical co., ltd. has a registered capital of 22 million yuan, of which: Zhejiang Jianfeng pharmaceutical co., ltd., the controlling subsidiary of the company, accounts for 90% and the company accounts for 10%. its registered address is 1180 huancheng east road, Jinhua city. Main business: drug business. Prepackaged food, hazardous chemicals, medical devices, etc. The drug business license mainly includes: sales of Chinese patent medicines, Chinese medicinal materials, Chinese medicinal tablets, chemical preparations, chemical raw materials, antibiotics, biochemical drugs, biological products, narcotic drugs, psychotropic drugs, etc. .
5, Zhejiang Jianfeng International Trade Co., Ltd., with a registered capital of 30 million yuan, of which: 93.33 of our company and 6.67 of Jianfeng Pharmaceutical Co., Ltd., registered address: 88 changchun West Road, Jindong Economic Development Zone, Zhejiang Province, mainly engaged in: licensed business items: freight transportation: general cargo transportation; Station yard: freight station (yard) operation (freight loading, storage and tally) (road transport operation license is valid until 2015 9 July 5 ). General business items: import and export of goods and technologies, sales of pharmaceutical intermediates, pharmaceutical equipment, daily chemicals, textiles, etc. that are permitted by national laws and regulations and do not require pre-approval; public bonded warehouse operation; business permitted by national laws and policies Consulting service activities (except futures, securities, and financial business consulting); carry out international transportation agency business for import and export goods.
Key audited 2013 financial data of the above subsidiaries (in: ten thousand yuan)
company name |
total assets |
asset-liability ratio% |
total operating income |
net profit attributable to owner of parent company |
Zhejiang Jianfeng Pharmaceutical Co., Ltd. |
83321.11 |
62.80 |
92418.02 |
3190.88 |
Daye Jianfeng Cement Co., Ltd. |
68282.37 |
33.71 |
62850.24 |
10531.00 |
Yunnan Jianfeng Cement Co., Ltd. |
55484.50 |
74.68 |
30852.77 |
1057.59 |
Jinhua Pharmaceutical Co., Ltd. |
32640.47 |
78.60 |
65684.78 | 290.07
|
The main contents of the guarantee provided by the 3.
1. Guarantee the loans of the holding subsidiary to financial institutions, set the following limits:
The guarantee within the above amount authorizes the chairman to execute it in batches.
above matters shall be submitted to the shareholders' meeting for deliberation.
4. the opinion of the board of directors
The above guaranteed companies are all controlling subsidiaries of the company. The company can effectively control the guarantee risks, and the board of directors agrees to the above guarantees. The three independent directors of the company issued an independent opinion that was expressly agreed.
5. Cumulative Number of External Guarantees and Number of Overdue Guarantees
As of the disclosure date of this announcement, the total amount of external guarantees approved by the company and its controlling subsidiaries is 650 million yuan, accounting for 37.42 of the total owner's equity attributable to the parent company in 2013 audited consolidated caliber. The total amount of guarantee approved by the company to the holding subsidiary is 400 million yuan, accounting for 23.03 of the total owner's equity attributable to the parent company in 2013.
As of the disclosure date of this announcement, the actual balance of external guarantees of the company and its controlling subsidiaries was 350 million yuan, accounting for 20.15 of the total owner's equity attributable to the parent company by the audited consolidated caliber in 2013; The actual balance of the company's guarantee to the holding subsidiary is 80 million yuan, accounting for 4.61 of the total owner's equity attributable to the parent company by the audited consolidated caliber in 2013.
As of the disclosure date of this announcement, the company has no overdue guarantee.
6. Reference Document Catalogue
1
, Resolution of the 14th Meeting of the 8th Board of Directors of the Company;2
, copy of the business license of the guarantor;hereby announces
Zhejiang Jianfeng Group Co., Ltd.
Board of Directors
April 15, 2014
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31